{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:23:05Z","timestamp":1788790985108,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11926-019-0844-7","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T07:02:37Z","timestamp":1563001357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Current Unmet Needs in Spondyloarthritis"],"prefix":"10.1007","volume":"21","author":[{"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,13]]},"reference":[{"issue":"10089","key":"844_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"\u2022\u2022 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4\n                      \n                    . A recent comprehensive review on spondyloarhtritis.","journal-title":"Lancet"},{"issue":"6","key":"844_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383. \n                      https:\/\/doi.org\/10.1136\/ard.2009.108233\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"844_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"844_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00002281-200007000-00002","volume":"12","author":"E Feldtkeller","year":"2000","unstructured":"Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol. 2000;12(4):239\u201347.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"844_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.2003.011247","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63(5):535\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"844_CR6","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/rheumatology\/kez090","volume":"58","author":"Imke Redeker","year":"2019","unstructured":"\u2022 Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford). 2019. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kez090\n                      \n                    . Recent data on diagnostic delay and factors associated with the delay.","journal-title":"Rheumatology"},{"issue":"8","key":"844_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/annrheumdis-2014-207151","volume":"74","author":"D Poddubnyy","year":"2015","unstructured":"\u2022 Poddubnyy D, van Tubergen A, Landewe R, Sieper J, van der Heijde D. Assessment of SpondyloArthritis international S. Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. Ann Rheum Dis. 2015;74(8):1483\u20137. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2014-207151\n                      \n                    . The ASAS endorsed recommendation for early referral of patients with suspicion of axial spondyloarthritis.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"844_CR8","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KA, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis. 2016;75(11):1958\u201363. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2015-208642\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"844_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40475","volume":"70","author":"J de Winter","year":"2018","unstructured":"de Winter J, de Hooge M, van de Sande M, de Jong H, van Hoeven L, de Koning A, et al. Magnetic resonance imaging of the sacroiliac joints indicating sacroiliitis according to the assessment of SpondyloArthritis International Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. Arthritis Rheumatol. 2018;70(7):1042\u20138. \n                      https:\/\/doi.org\/10.1002\/art.40475\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"844_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.40429","volume":"70","author":"U Weber","year":"2018","unstructured":"Weber U, Jurik AG, Zejden A, Larsen E, Jorgensen SH, Rufibach K, et al. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: exploring \u201cbackground noise\u201d toward a data-driven definition of sacroiliitis in early spondyloarthritis. Arthritis Rheumatol. 2018;70(5):736\u201345. \n                      https:\/\/doi.org\/10.1002\/art.40429\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"844_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/ard.2005.051045","volume":"65","author":"M Rudwaleit","year":"2006","unstructured":"Rudwaleit M, Feldtkeller E, Sieper J. Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside. Ann Rheum Dis. 2006;65(9):1251\u20132. \n                      https:\/\/doi.org\/10.1136\/ard.2005.051045\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"844_CR12","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1038\/s41467-018-06933-4","volume":"9","author":"I Cambre","year":"2018","unstructured":"Cambre I, Gaublomme D, Burssens A, Jacques P, Schryvers N, De Muynck A, et al. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nat Commun. 2018;9(1):4613. \n                      https:\/\/doi.org\/10.1038\/s41467-018-06933-4\n                      \n                    .","journal-title":"Nat Commun"},{"issue":"4","key":"844_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38(4):499\u2013505.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"844_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2016.42","volume":"12","author":"J Sieper","year":"2016","unstructured":"Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016;12(5):282\u201395. \n                      https:\/\/doi.org\/10.1038\/nrrheum.2016.42\n                      \n                    .","journal-title":"Nat Rev Rheumatol"},{"issue":"7090","key":"844_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235\u20138. \n                      https:\/\/doi.org\/10.1038\/nature04753\n                      \n                    .","journal-title":"Nature"},{"issue":"11","key":"844_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Wellcome Trust Case Control C, Australo-Anglo-American Spondylitis C, Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39(11):1329\u201337. \n                      https:\/\/doi.org\/10.1038\/ng.2007.17\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"5","key":"844_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.berh.2010.05.001","volume":"24","author":"D Poddubnyy","year":"2010","unstructured":"Poddubnyy D, Appel H, Sieper J. Investigation of involved tissue in axial spondyloarthritis\u2014what have we learnt from immunohistochemical studies? Best Pract Res Clin Rheumatol. 2010;24(5):715\u20139.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"844_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069\u201376. \n                      https:\/\/doi.org\/10.1038\/nm.2817\n                      \n                    .","journal-title":"Nat Med"},{"key":"844_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","volume":"57","author":"D Poddubnyy","year":"2017","unstructured":"\u2022 Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor alpha, interleukin 17, or both? Rheumatology (Oxford). 2017;57:1145\u201350. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kex361\n                      \n                    . An extensive discussion of possible ways of identification of the optimal treatment strategies in spondyloarthritis.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"844_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/14712598.2019.1605352","volume":"19","author":"Murat Torgutalp","year":"2019","unstructured":"Torgutalp M, Poddubnyy D. IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin Biol Ther. 2019;1\u201311. \n                      https:\/\/doi.org\/10.1080\/14712598.2019.1605352\n                      \n                    .","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"6","key":"844_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"\u2022\u2022 van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770\n                      \n                    . The current set of management recommendations in for axial spondyloarthritis.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"844_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76(3):571\u201392. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-210023\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"844_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611. \n                      https:\/\/doi.org\/10.1002\/art.40753\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"844_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258\u201370. \n                      https:\/\/doi.org\/10.1002\/art.40728\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"844_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, Ostergaard M, Wei JC, Sieper J, Jarvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295\u2013302. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2018-213328\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"844_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/cei.12830","volume":"186","author":"M Noack","year":"2016","unstructured":"Noack M, Ndongo-Thiam N, Miossec P. Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells. Clin Exp Immunol. 2016;186(1):64\u201374. \n                      https:\/\/doi.org\/10.1111\/cei.12830\n                      \n                    .","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"844_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1189\/jlb.3HI1215-542R","volume":"100","author":"T Noordenbos","year":"2016","unstructured":"Noordenbos T, Blijdorp I, Chen S, Stap J, Mul E, Canete JD, et al. Human mast cells capture, store, and release bioactive, exogenous IL-17A. J Leukoc Biol. 2016;100(3):453\u201362. \n                      https:\/\/doi.org\/10.1189\/jlb.3HI1215-542R\n                      \n                    .","journal-title":"J Leukoc Biol"},{"key":"844_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3389\/fimmu.2018.00795","volume":"9","author":"N Tamassia","year":"2018","unstructured":"Tamassia N, Arruda-Silva F, Calzetti F, Lonardi S, Gasperini S, Gardiman E, et al. A reappraisal on the potential ability of human neutrophils to express and produce IL-17 family members in vitro: failure to reproducibly detect it. Front Immunol. 2018;9:795. \n                      https:\/\/doi.org\/10.3389\/fimmu.2018.00795\n                      \n                    .","journal-title":"Front Immunol"},{"issue":"4","key":"844_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","volume":"43","author":"JS Lee","year":"2015","unstructured":"\u2022 Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43(4):727\u201338. \n                      https:\/\/doi.org\/10.1016\/j.immuni.2015.09.003\n                      \n                    . A study providing evidence for IL-23 independent production of IL-17.","journal-title":"Immunity"},{"issue":"2","key":"844_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1124\/jpet.115.224246","volume":"354","author":"PR Mangan","year":"2015","unstructured":"Mangan PR, Su LJ, Jenny V, Tatum AL, Picarillo C, Skala S, et al. Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity. J Pharmacol Exp Ther. 2015;354(2):152\u201365. \n                      https:\/\/doi.org\/10.1124\/jpet.115.224246\n                      \n                    .","journal-title":"J Pharmacol Exp Ther"},{"issue":"9894","key":"844_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2\n                      \n                    .","journal-title":"Lancet"},{"issue":"4","key":"844_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4):632\u20137. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.011\n                      \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"844_CR33","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","volume":"72","author":"JE Paramarta","year":"2013","unstructured":"Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2013;72(11):1793\u20139. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2012-202245\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"844_CR34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","volume":"76","author":"P Carron","year":"2017","unstructured":"Carron P, Varkas G, Cypers H, Van Praet L, Elewaut D, Van den Bosch F, et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis. 2017;76(8):1389\u201395. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-210775\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"844_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.39008","volume":"67","author":"P Mease","year":"2015","unstructured":"Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015;67(4):914\u201323. \n                      https:\/\/doi.org\/10.1002\/art.39008\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"844_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. \n                      https:\/\/doi.org\/10.1038\/nrrheum.2015.167\n                      \n                    .","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"844_CR37","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340\u20137. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"key":"844_CR38","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/s0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2378\u201387. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(18)32463-2\n                      \n                    .","journal-title":"Lancet"},{"issue":"9","key":"844_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","volume":"19","author":"D Poddubnyy","year":"2017","unstructured":"\u2022\u2022 Poddubnyy D, Sieper J. Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep. 2017;19(9):55. \n                      https:\/\/doi.org\/10.1007\/s11926-017-0681-5\n                      \n                    . A comprehensive review on the topic of structural damage progression in axial spondyloarthritis.","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"844_CR40","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063\u201370. \n                      https:\/\/doi.org\/10.1002\/art.23901\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"5","key":"844_CR41","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324\u201331. \n                      https:\/\/doi.org\/10.1002\/art.23471\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"4","key":"844_CR42","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. \n                      https:\/\/doi.org\/10.1186\/ar2794\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"844_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Hermann KA, Landewe RBM, Machado PM, Maksymowych WP, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018;77(5):699\u2013705. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2017-212377\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"844_CR44","doi-asserted-by":"publisher","first-page":"e0177231","DOI":"10.1371\/journal.pone.0177231","volume":"12","author":"F Maas","year":"2017","unstructured":"Maas F, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PLoS One. 2017;12(6):e0177231. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0177231\n                      \n                    .","journal-title":"PLoS One"},{"issue":"1","key":"844_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"\u2022 Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77(1):63\u20139. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2017-211544\n                      \n                    . A recent study indicating an association between the depth of inflammation suppression and inhibition of radiographic spinal progression.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"844_CR46","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354. \n                      https:\/\/doi.org\/10.1002\/art.38070\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"844_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"\u2022\u2022 Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734\n                      \n                    . The current treat-to-target recommendations for spondyloarthritis.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"844_CR48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"\u2022\u2022 Gravallese EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;14(11):631\u201340. \n                      https:\/\/doi.org\/10.1038\/s41584-018-0091-8\n                      \n                    . Summary of the recent data on the effect of IL-23\/IL-17 on bone.","journal-title":"Nat Rev Rheumatol"},{"key":"844_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2018","unstructured":"Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford). 2018;58:859\u201368. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/key375\n                      \n                    .","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"844_CR50","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756\u201365.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"844_CR51","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438\u201343. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2015-207897\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"844_CR52","doi-asserted-by":"publisher","first-page":"e014591","DOI":"10.1136\/bmjopen-2016-014591","volume":"7","author":"F Proft","year":"2017","unstructured":"Proft F, Muche B, Listing J, Rios-Rodriguez V, Sieper J, Poddubnyy D. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL)\u2014an open-label randomized controlled multicenter trial. BMJ Open. 2017;7(6):e014591. \n                      https:\/\/doi.org\/10.1136\/bmjopen-2016-014591\n                      \n                    .","journal-title":"BMJ Open"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0844-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-019-0844-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0844-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T23:32:42Z","timestamp":1594510362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-019-0844-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,13]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s11926-019-0844-7","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,13]]},"assertion":[{"value":"13 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Joachim Sieper reports grants and personal fees from Abbvie, Janssen, MSD, and Pfizer and personal fees from Lilly, Novartis, Roche, UCB, and Sun Pharma.Denis Poddubnyy reports grants and personal fees from Abbvie, MSD, Novartis, and Pfizer, and personal fees from BMS, Lilly, Roche, UCB, and Celgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"43"}}